Improve Your Financial Performance with Vasc-Alert
Vasc-Alert is an investment – in your patients, your operation and your bottom line. The value it generates in improved patient satisfaction and enhanced care is not easily quantified but is an invaluable benefit. Clearly, patient outcomes and care are of utmost priority. However, Vasc-Alert rewards users by also boosting financial performance and directly benefitting the bottom line.
Vasc-Alert accurately identifies dialysis patients with possible stenosis early-on, before costly complications due to thrombosis can occur. This reduces excessive missed treatments and extra costs of catheter use. It also improves operations and requires less staff time and resources to manage complications. Over time, studies show these cost savings more than pay for the Vasc-Alert surveillance system. It’s a win-win investment in your patients and your organization.
Vasc-Alert conducted a multi-center analysis of the incidence of missed treatments and catheter usage with AV access capable patients as a function of access complications. 850 patients from 6 centers were divided into 4 categories based on their treatment and intervention records:
- Patients without access issues (62%).
- Patients undergoing angioplasty only (18%).
- Patients who had a thrombectomy (2%).
- Patients who used both an AV access and a catheter (18%).
Twenty percent of the patients fell into the latter two categories, which can be considered as ‘patients with access complications’. This group missed an average of 3.7 treatment days more than the patients who did not have access complications and the number of treatments on a catheter for AV access capable patients totaled 6.8% of all treatments for AV patient.
These findings carry significant costs. Missed treatments translate to missed revenue and catheter treatments costs $25 to $30 more under the bundle. Multiplying these costs through by the patient counts results in costs that total $450 to $470 per AV access patient per year depending on your cost assumptions.
Translating these findings to the typical center with 100 AV access patients, you are looking at ‘hidden costs’ of $45,000 to $47,000. While every access will eventually clot and fail, if you can reduce the principle cause of access complications (thrombosis) by better vascular access management, it is possible that the dialysis center can make far more than the cost of Vasc-Alert ($10,000).
In addition, the new QIP program from CMS has identified a number of clinical metrics that have to be met or the center will suffer a decrease in reimbursement. Many of these quality indicators assume a functioning, patent, AV access. For example, it is very difficult to achieve adequacy goals with an AV access 80% occluded or the patient using a catheter.
In summary, the use of Vasc-Alert at the heart of a good vascular access program can provide significant value, both clinically for the patients and financially for the center.
For a more detailed analysis of the financial benefits of using Vasc-Alert, see the Vasc-Alert Retrospective Analysis Summary.